

**2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM**



Nuedexta - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	<b>Specialty/facility name (if applicable):</b>	

**REQUEST FOR EXPEDITED REVIEW:** By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

**Please answer the following questions and sign.**

**Q1. Does the patient have a confirmed diagnosis of pseudobulbar affect (PBA)?**

Yes

No

**Q2. Is the patient 18 years of age or older?**

Yes

No

**Q3. Is the requested drug being prescribed by or in consultation with a neurologist?**

Yes

No

**Q4. Does the patient have any of the following: A) history of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions, B) known hypersensitivity to dextromethorphan, C) prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure, D) complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block?**

Yes

No

**Q5. Will the requested drug be used concomitantly with any of the following: A) quinidine, B) quinine, C) mefloquine, D) drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g. thioridazine or pimozide)?**

Yes

No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM

Nuedexta - Medicare

Phone: 215-991-4300

Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b>
Q6. Will the requested drug be used with a monoamine oxidase inhibitor (MAOI) or within 14 days of stopping a MAOI? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. Is the patient at risk of QT prolongation and torsades de pointes? [Note: patients at risk of QT prolongation and torsades de pointes include recipients concomitantly taking any CYP3A4 inhibitors or medications which may prolong the QT interval and recipients with left ventricular hypertrophy or left ventricular dysfunction.] <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. Will the patient have a baseline EKG and an EKG evaluation 3 to 4 hours after the first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Requested Duration: <input type="checkbox"/> 12 Months <input type="checkbox"/> Other	
Q10. Additional Information:	

Prescriber Signature

Date

2024 Medicare Prior Authorization Request